Parkinson Disease, Drug-Induced
GPTKB entity
Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:disease
|
| gptkbp:affects |
central nervous system
|
| gptkbp:alsoKnownAs |
gptkb:Drug-Induced_Parkinsonism
Secondary Parkinsonism |
| gptkbp:causedBy |
gptkb:valproic_acid
gptkb:reserpine gptkb:metoclopramide antipsychotic drugs medications dopamine antagonists |
| gptkbp:designer |
true
|
| gptkbp:diagnosedBy |
neurological examination
clinical history |
| gptkbp:diseaseCategory |
neurological disorder
|
| gptkbp:distinctiveFeature |
gptkb:idiopathic_Parkinson's_disease
|
| gptkbp:firstDescribed |
1950s
|
| gptkbp:frequency |
common cause of parkinsonism
|
| https://www.w3.org/2000/01/rdf-schema#label |
Parkinson Disease, Drug-Induced
|
| gptkbp:ICD-10_code |
G21.1
|
| gptkbp:MeSH_ID |
D010300
|
| gptkbp:prevalence |
higher in psychiatric patients
|
| gptkbp:relatedTo |
extrapyramidal symptoms
|
| gptkbp:riskFactor |
elderly
female gender |
| gptkbp:symptom |
bradykinesia
postural instability rigidity tremor |
| gptkbp:treatment |
discontinuation of causative drug
anticholinergic medications |
| gptkbp:bfsParent |
gptkb:D010141
|
| gptkbp:bfsLayer |
7
|